Boston Scientific to Present at Wells Fargo Healthcare Conference Ahead of Q3 Earnings
The medical device maker announces its participation in a major industry conference scheduled for early September, with third-quarter results expected in October.
Conference Participation
Boston Scientific Corporation (NYSE: BSX) announced Monday that it will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026. The Marlborough, Massachusetts-based medical device manufacturer, which carries a market capitalization of approximately $71 billion, will be represented by Chairman and CEO Mike Mahoney and Senior Vice President Kenneth Stein, M.D.
The company's stock last closed at $49.31.
Upcoming Earnings and Market Events
According to MarginX data, Boston Scientific is expected to report its third-quarter 2026 results on October 21, 2026, approximately six weeks following the Wells Fargo conference. The timing of the conference presentation may provide investors with management's perspective on business trends ahead of the formal earnings release.
The broader market calendar includes a Federal Open Market Committee rate decision and projections scheduled for September 16, followed by another FOMC rate decision on October 28, bracketing the company's earnings announcement.
Recent Insider Activity
MarginX data shows notable recent insider purchasing activity at Boston Scientific. CEO Michael Mahoney acquired 186,240 shares, while Director David C. Habiger made two separate purchases totaling 2,240 shares. Insider buying can sometimes signal management confidence in the company's prospects, though such transactions occur for various reasons and do not guarantee future performance.
Industry Context
The Wells Fargo Healthcare Conference is a significant annual event that brings together management teams from leading healthcare companies with institutional investors. Boston Scientific's participation provides an opportunity for the company to discuss its strategic priorities and market position within the medical device sector.
The company operates in a competitive industry focused on developing innovative medical solutions across cardiovascular, rhythm management, and other therapeutic areas.
This article was generated by MarginX from public news on 2026-08-10. It is not investment advice.